


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Nucleoside Analogues of Purine with a 1,2-Disubstituted Cyclopentene Ring

P. Besada^a; C. Terán^a; L. Santana^b; M. Teijeira^b; E. Uriarte^b

^a Departamento de Química Física y Química Orgánica, Universidad de Vigo, Spain ^b Facultad de Farmacia, Universidad de Santiago de Compostela, Spain

To cite this Article Besada, P. , Terán, C. , Santana, L. , Teijeira, M. and Uriarte, E.(1999) 'Nucleoside Analogues of Purine with a 1,2-Disubstituted Cyclopentene Ring', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 725 — 726

To link to this Article: DOI: 10.1080/15257779908041554

URL: <http://dx.doi.org/10.1080/15257779908041554>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDE ANALOGUES OF PURINE WITH A 1,2-DISUBSTITUTED CYCLOPENTENE RING

P. Besada^a, C. Terán^{a*}, L. Santana^b, M. Teijeira^b and E. Uriarte^b

^a*Departamento de Química Física y Química Orgánica, Universidad de Vigo, Spain*

^b*Facultad de Farmacia, Universidad de Santiago de Compostela, Spain*


ABSTRACT. One, two-disubstituted carbonucleoside analogues of purine with unsaturated carbocyclic were synthesized by construction of the heterocyclic base about the primary amino group of the amino alcohol **4** intermediate, which was also synthesized in good yield starting from cyclopentadiene.

Following our previous work on carbocyclic nucleoside analogues one, two-disubstituted carbonucleosides (OTCs-cyclopentanes with a hydroxymethyl group and the heterocyclic base attached to contiguous ring carbons), we describe here the preparation of compounds with an unsaturation in the 2',3' position of the carbocyclic ring. These compounds can be considered as analogues of carbovir and other nucleoside analogues with interesting pharmacological properties.

Racemic mixtures of compounds **6** - **8** with *cis* stereochemistry, were prepared as shown in scheme 1. The key intermediate (\pm) *cis*-2-amino-3-cyclopentenylmethanol (**4**) was synthesized in good yield from the cyclopentadiene in 4 steps: treatment of cyclopentadiene (**1**) with chlorosulfonyl isocyanate to obtain the lactame **2** corresponding to an 2+2 cycloaddition; hydrolysis of this lactame to 2-amino-3-cyclopentenecarboxylic acid; formation of the methyl ester via acid chloride; and final reduction of the resulting amino ester **3** with lithium borohydride. The purine base was then constructed about the primary amino group of these intermediates.¹ To obtain the 6-substituted purines (**6a** - **8a**), the amino alcohol **4** was reacted with 5-amino-4,6-dichloropyrimidine, which afforded **5a**, and to obtain the 2,6-disubstituted purines (**6b** - **8b**), the amino alcohol **4** was firstly reacted with 2-amino-4,6-dichloropyrimidine, and then a second amino group was introduced at position 5 of the pyrimidine ring by reaction with p-

chlorobenzenediazonium chloride followed by reduction to afford the compound **5b**. The fused imidazole ring was then formed in compound **5a** or **5b**, by reaction with ethylorthoformate in acid medium, which afforded respectively 6-chloropurine **6a** and 2-amino-6-chloropurine **6b**.

The 6-hydroxy analogues **7a** and **7b** were prepared in good yield by treatment of **6a** and **6b** respectively with NaOH and similar good yields of the 6-amino analogues **8a** and **8b** were obtained by amination of **6a** and **6b** in metanol.²



i: CSI, ether dry. ii: a) HCl 12M; b) MeOH dry, Cl₂SO; c) amberlite IRA 420(OH)ion-exchange resin. iii: LiBH₄, THF dry. iv: 5-amino-4,6-dichloropyrimidine, n-BuOH, Et₃N. v: a) 2-amino-4,6-dichloropyrimidine, n-BuOH, Et₃N; b) p-chlorophenyldiazonium chloride, AcONa.3H₂O; c) Zn, AcOH, H₂O, EtOH. vi: CH(EtO)₃, HCl 12M. vii: NaOH 0.5M. viii: MeOH, NH₄OH.

SCHEME 1

REFERENCES

1. Vince, R.; Hua, M. *J. Med. Chem.*, **1990**, 33, 17-21.
2. All compounds had spectral and analytical data consistent with their structures.